TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life.
Luca RicheldiPietro SchinoElena BargagliAlberto RicciAlberto RoccaFrancesca MarchesaniAlfio PennisiGianna CamiciottoliMaria D'AmatoFrancesco MacagnoUlrica Scaffidi ArgentinaEleonora IngrassiaAlessio PirainoPublished in: International journal of chronic obstructive pulmonary disease (2024)
TRITRIAL showed that the BDP/FF/G fixed combination is effective and safe in patients with moderate-severe COPD and poorly controlled disease, improving patients' HRQoL, sleep quality, adherence and inhaler usability and reducing COPD symptoms and the risk of exacerbation in a real-life setting.
Keyphrases
- sleep quality
- chronic obstructive pulmonary disease
- lung function
- ejection fraction
- end stage renal disease
- depressive symptoms
- newly diagnosed
- prognostic factors
- stem cells
- healthcare
- early onset
- metabolic syndrome
- adipose tissue
- cystic fibrosis
- patient reported outcomes
- cell therapy
- mesenchymal stem cells
- drug induced
- extracorporeal membrane oxygenation
- social media